Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and...
MMRF continues to drive the critical global research collaborations that lead to scientific breakthroughs and improved patient outcomesNORWALK, Conn., Sept....
First European launch of EKTERLY expected in Germany Q4 2025 EKTERLY now approved in the US, EU, UK and Switzerland...
BIRMINGHAM, Ala., Sept. 19, 2025 /PRNewswire/ -- Acclinate, the health equity company pioneering community-powered engagement and inclusive clinical trial enrollment,...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in...
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with...
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an...
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,...
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,...
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerabilitySAN DIEGO, Sept. 19, 2025...
Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –...
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported...
Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH LONDON, UK / ACCESS Newswire...
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for...
The addition of Blue Spark Technologies, Inc. and QT Medical as device partners signals exciting growth for HeartcoR Solutions as...
The new site solution enables centralized referral management, real-time trial updates and enhanced physician communication to improve patient retention for...
SAN ANTONIO, Sept. 18, 2025 /PRNewswire/ -- We are proud to announce that RealTime eClinical Solutions has won the Innovation...
DENVER, CO AND MAHWAH, NJ / ACCESS Newswire / September 18, 2025 / ForCast Orthopedics, Inc. and KORU Medical Systems,...